Provided herein are PLpro inhibitors and methods of treating and/or preventing an infection caused by a coronavirus by administration of one or more of said PLpro inhibitors to a subject in need thereof, as well as pharmaceutical formulations and kits for use in these methods.

UV-absorbing compounds are provided that have at least one reactive hydrogen. These compounds have structures: ##STR00001##
wherein the generic notations have meanings as described herein. Also provided are formulations comprising a UV-absorbing compounds.

UV-absorbing compounds are provided that have at least one reactive hydrogen. These compounds have structures: ##STR00001##
wherein the generic notations have meanings as described herein. Also provided are formulations comprising a UV-absorbing compounds.

Described herein are UV-absorbing vinylic monomers and their uses in preparing UV-absorbing contact lenses capable of blocking ultra-violet (UV) radiation and violet radiation with wavelengths from 380 nm to 440 nm, thereby protecting eyes to some extent from damages caused by UV radiation and potentially from violet radiation.

Described herein are UV-absorbing vinylic monomers and their uses in preparing UV-absorbing contact lenses capable of blocking ultra-violet (UV) radiation and violet radiation with wavelengths from 380 nm to 440 nm, thereby protecting eyes to some extent from damages caused by UV radiation and potentially from violet radiation.

The present disclosure provides compounds of formula (I) that function as modulators of mitochondrial aldehyde dehydrogenase-2 (ALDH2) activity, and methods of preparing these compounds.

The present disclosure provides compounds of formula (I) that function as modulators of mitochondrial aldehyde dehydrogenase-2 (ALDH2) activity, and methods of preparing these compounds.

Provided herein are deuterated compounds and compositions useful in increasing PPAR activity. The compounds have a formula

##STR00001##

where L.sup.5 comprises at least one deuterium. Exemplary species include

##STR00002##

The compounds and compositions provided herein are useful for the treatment of PPAR related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).

Provided herein are deuterated compounds and compositions useful in increasing PPAR activity. The compounds have a formula

##STR00001##

where L.sup.5 comprises at least one deuterium. Exemplary species include

##STR00002##

The compounds and compositions provided herein are useful for the treatment of PPAR related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).

In an embodiment of the invention, a composition for treating a cell population comprises an Affinity Medicant Conjugate (AMC). The medicant moiety can be a toxin including an acylfulvene or a drug moiety. The affinity moiety can be an antibody, a binding protein, a steroid, a lipid, a growth factor, a protein, a peptide or non peptidic. The affinity moiety can be covalently bound to the medicant via a linker. Novel linkers that can be directed to cysteine, arginine or lysine residues based on solution pH allow greater flexibility in preserving and/or generating specific epitopes in the AMC.